112 related articles for article (PubMed ID: 29958636)
21. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
[TBL] [Abstract][Full Text] [Related]
22. The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Jia H; Ren W; Feng Y; Wei T; Guo M; Guo J; Zhao J; Song X; Wang M; Zhao T; Wang H; Feng Z; Tian Z
Int J Oncol; 2018 Sep; 53(3):949-960. PubMed ID: 30015838
[TBL] [Abstract][Full Text] [Related]
23. Pimozide treatment of the negative schizophrenic syndrome: an open trial.
Feinberg SS; Kay SR; Elijovich LR; Fiszbein A; Opler LA
J Clin Psychiatry; 1988 Jun; 49(6):235-8. PubMed ID: 3288615
[TBL] [Abstract][Full Text] [Related]
24. Pimozide: use in dermatology.
van Vloten WA
Dermatol Online J; 2003 Mar; 9(2):3. PubMed ID: 12639456
[TBL] [Abstract][Full Text] [Related]
25. Glioblastoma stem cells: a new target for metformin and arsenic trioxide.
Carmignani M; Volpe AR; Aldea M; Soritau O; Irimie A; Florian IS; Tomuleasa C; Baritchii A; Petrushev B; Crisan G; Valle G
J Biol Regul Homeost Agents; 2014; 28(1):1-15. PubMed ID: 24750786
[TBL] [Abstract][Full Text] [Related]
26. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor targeting and challenges in glioblastoma.
Thorne AH; Zanca C; Furnari F
Neuro Oncol; 2016 Jul; 18(7):914-8. PubMed ID: 26755074
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of the dopaminergic inhibitor pimozide in previously treated melanoma patients.
Neifeld JP; Tormey DC; Baker MA; Meyskens FL; Taub RN
Cancer Treat Rep; 1983 Feb; 67(2):155-7. PubMed ID: 6825122
[TBL] [Abstract][Full Text] [Related]
29. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.
Lefranc F; Facchini V; Kiss R
Oncologist; 2007 Dec; 12(12):1395-403. PubMed ID: 18165616
[TBL] [Abstract][Full Text] [Related]
30. Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study.
Haas S; Beckmann H
Pharmacopsychiatria; 1982 Mar; 15(2):70-4. PubMed ID: 7043498
[TBL] [Abstract][Full Text] [Related]
31. Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme.
Garrido W; Rocha JD; Jaramillo C; Fernandez K; Oyarzun C; San Martin R; Quezada C
Curr Drug Targets; 2014; 15(10):931-42. PubMed ID: 25174341
[TBL] [Abstract][Full Text] [Related]
32. Serum prolactin and antipsychotic responses to pimozide in schizophrenia.
Siris SG; van Kammen DP; De Fraites EG
Psychopharmacol Bull; 1978 Jan; 14(1):11-4. PubMed ID: 625528
[No Abstract] [Full Text] [Related]
33. Timing recalibration in childhood Tourette syndrome associated with persistent pimozide treatment.
Vicario CM; Gulisano M; Martino D; Rizzo R
J Neuropsychol; 2016 Sep; 10(2):211-22. PubMed ID: 25705969
[TBL] [Abstract][Full Text] [Related]
34. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
[TBL] [Abstract][Full Text] [Related]
35. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
36. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?
van Kammen DP; Hommer DW; Malas KL
Neuropsychobiology; 1987; 18(3):113-7. PubMed ID: 3453426
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13.
Strobl JS; Peterson VA
J Pharmacol Exp Ther; 1992 Oct; 263(1):186-93. PubMed ID: 1403784
[TBL] [Abstract][Full Text] [Related]
38. Discovery of pimozide derivatives as novel T-type calcium channel inhibitors with little binding affinity to dopamine D
Kasanami Y; Ishikawa C; Kino T; Chonan M; Toyooka N; Takashima Y; Iba Y; Sekiguchi F; Tsubota M; Ohkubo T; Yoshida S; Kawase A; Okada T; Kawabata A
Eur J Med Chem; 2022 Dec; 243():114716. PubMed ID: 36075145
[TBL] [Abstract][Full Text] [Related]
39. [The validation of the expediency of using pimozide in treating the hypomania syndrome of alcoholic origin].
Serebrennikova OA
Lik Sprava; 2000; (3-4):80-3. PubMed ID: 10921270
[TBL] [Abstract][Full Text] [Related]
40. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
